We are live on ! Find out more
JAGX icon

Jaguar Health

0.3532 USD
-0.0267
7.03%
At close Updated Nov 18, 4:00 PM EST
Pre-market
After hours
0.3626
+0.0094
2.66%
1 day
-7.03%
5 days
-24.85%
1 month
-87.48%
3 months
-97.59%
6 months
-99.36%
Year to date
-99.93%
1 year
-99.96%
5 years
-100%
10 years
-100%
 

About: Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Employees: 47

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 9.1%
Neutral 68.2%
Negative 22.7%
Neutral
Seeking Alpha
1 day ago
Jaguar Health, Inc. (JAGX) Q3 2026 Earnings Call Prepared Remarks Transcript
Jaguar Health, Inc. (JAGX) Q3 2026 Earnings Call Prepared Remarks Transcript
Jaguar Health, Inc. (JAGX) Q3 2026 Earnings Call Prepared Remarks Transcript
Neutral
Accesswire
29 days ago
Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder
Mutation of the GUCY2C gene is the third IF-related congenital enteropathy, in addition to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF), for which crofelemer has demonstrated benefit in reducing parenteral support needs in pediatric patients Company plans to file NDA for crofelemer for MVID in mid-2027 to obtain FDA approval SAN FRANCISCO, CA / ACCESS Newswire / October 21, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Jaguar family company Napo Pharmaceuticals (Napo) has been continuing to provide the company's novel crofelemer powder for oral solution for several weeks for the treatment of intestinal failure (IF) in an infant patient with GUCY2C mutation resulting in congenital sodium diarrhea (CSD). Liquid oral crofelemer therapy is well tolerated by this patient and has demonstrated reduced needs for daily and weekly parenteral support (PS) with no significant clinical or laboratory abnormalities.
Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder
Neutral
Accesswire
1 month ago
Jaguar Health Provides Update Regarding Special Stock Dividend
Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternatives Jaguar's rare disease intestinal failure development program for microvillus inclusion disease (MVID) and short bowel syndrome for crofelemer powder for oral solution is expected to continue to provide clinical milestones, including a planned New Drug Application (NDA) filing for crofelemer for MVID in mid-2027 SAN FRANCISCO, CA / ACCESS Newswire / October 14, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today provided an update in connection with the Company's previously announced special stock dividend (the "Special Stock Dividend"), which is payable on October 15, 2026, to holders of Jaguar common stock and certain outstanding warrants as of record on October 13, 2026, to announce that The Nasdaq Stock Market LLC ("Nasdaq") has indicated that the ex-dividend date for the Special Stock Dividend is October 16, 2026 (the "Ex-Dividend Date"). The Special Stock Dividend consists of the Company's Series R Convertible Preferred Stock (the "Preferred Stock").
Jaguar Health Provides Update Regarding Special Stock Dividend
Neutral
Accesswire
1 month ago
Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for SBS-IF and microvillus inclusion disease (MVID) for crofelemer powder for oral solution, targeting a mid-2027 NDA filing for MVID SAN FRANCISCO, CA / ACCESS Newswire / October 14, 2026 / Jaguar Health, Inc. (Nasdaq:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today provided a recap of the positive preliminary results presented on October 13, 2026 at the American College of Gastroenterology Annual Scientific Meeting (ACG 2026) for the ongoing open-label pilot study of the company's crofelemer powder for oral solution in adult patients with Type 1 short bowel syndrome (T1SBS) with intestinal failure (SBS-IF). The abstract presented at ACG 2026, titled The Use of Crofelemer in Reducing Ostomy Output in Patients With Type 1 Short Bowel Syndrome: An Open Label Pilot Study, can be viewed by clicking here.
Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer
Neutral
Accesswire
1 month ago
Reminder: Today, October 13, 2026, is the Record Date for Jaguar Health's Special Stock Dividend
Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternatives Jaguar's rare disease intestinal failure development program for microvillus inclusion disease (MVID) and short bowel syndrome for crofelemer powder for oral solution is expected to continue to provide clinical milestones, including a planned New Drug Application (NDA) filing for crofelemer for MVID in mid-2027 SAN FRANCISCO, CA / ACCESS Newswire / October 13, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today issued a reminder that today, October 13, 2026, is the Record Date for the Company's special stock dividend (the "Special Stock Dividend"). As announced, Jaguar's Board of Directors declared a Special Stock Dividend to holders of Jaguar Common Stock and certain outstanding warrants as of record on October 13, 2026.
Reminder: Today, October 13, 2026, is the Record Date for Jaguar Health's Special Stock Dividend
Neutral
Accesswire
1 month ago
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and short bowel syndrome (SBS) for crofelemer powder for oral solution, targeting an NDA filing for MVID mid-2027 A recent Rareatives article shares the story of a young child living with MVID, highlighting the importance of family perspectives, supportive communication, and collaboration with clinicians in addressing rare intestinal diseases SAN FRANCISCO, CA / ACCESS Newswire / October 6, 2026 / Jaguar Health, Inc. (Nasdaq:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is a sponsor of the 2nd Best of Elite Ped-GI meeting in Abu Dhabi in the United Arab Emirates and is also sponsoring a panel discussion titled Intestinal Barrier Beyond Total Parenteral Nutrition (TPN) on October 30, 2026 at the meeting. Participants in the panel discussion include Dr. Mohamad Miqdady, Dr. Christos Tzivinikos, and Pravin Chaturvedi, PhD, Napo's and Jaguar's Chief Scientific Officer and Chair of the Scientific Advisory Board.
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi
Neutral
Accesswire
1 month ago
Jaguar Health Announces a Special Stock Dividend
Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternatives SAN FRANCISCO, CA / ACCESS Newswire / October 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today announced that its Board of Directors has declared a special stock dividend (the "Special Stock Dividend") to holders of Jaguar Common Stock and certain outstanding warrants as of record on October 13, 2026. The Special Stock Dividend will consist of the Company's Series R Convertible Preferred Stock (the "Preferred Stock").
Jaguar Health Announces a Special Stock Dividend
Neutral
Accesswire
1 month ago
Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS-IF for crofelemer powder for oral solution, targeting an NDA filing for MVID mid-2027 SAN FRANCISCO, CA / ACCESS Newswire / September 29, 2026 / Jaguar Health, Inc. (Nasdaq:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced the acceptance of an abstract on preliminary results of an ongoing open-label study of the company's crofelemer powder for oral solution in adult patients with short bowel syndrome with intestinal failure (SBS-IF) for presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG 2026). ACG 2026 takes place October 9-14, 2026 in Nashville, Tennessee.
Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting
Positive
24/7 Wall Street
1 month ago
Jaguar Health Soars 32% as Rare-Disease Pipeline News Meets Thin Post-Split Float
A rare-disease pipeline update and a thin post-split float are combining to send Jaguar Health (NASDAQ:JAGX) sharply higher. Jaguar Health stock is up 32% to $9.32 in morning trading, a surge rooted in company-specific forces.
Jaguar Health Soars 32% as Rare-Disease Pipeline News Meets Thin Post-Split Float
Positive
Benzinga
1 month ago
Jaguar Health Stock Surges Friday: What's Happening?
Jaguar Health Inc. (NASDAQ:JAGX) shares are surging Friday morning, reversing Thursday's dilution-driven sell-off after the company announced additional debt-for-equity exchanges that reduced its outstanding debt by over $6.7 million and successfully retired a major promissory note.
Jaguar Health Stock Surges Friday: What's Happening?
Price charts implemented using Lightweight Charts™